C. Difficile

Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.

The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.

Unnecessary antibiotics for viral infections and incorrect prescriptions for bacterial infections have significant consequences, including increased adverse effects and healthcare expenditures.

As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.

The federal lawsuit filed in court looks to stop the government’s plan to negotiate therapy prices.

With the CDC’s recent warning about it, this fungal infection is becoming more prevalent and is often multidrug resistant. Here are some infection prevention strategies to protect against its spread in health care facilities, where it is most common.

The federal agency gave Merck the nod to use the company's antiviral as prophylaxis for Cytomegalovirus Disease (CMV), postoperatively.

Findings indicate that while the severity of health impairment decreases over time, 18% of unvaccinated participants still experience symptoms up to 2 years after infection.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.

Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.

The Mexican Ministry of Health sent the CDC a list of over 200 US patients who may have been exposed to the fungal infection.

There has been a low uptake of bivalent mRNA booster vaccines in older adults, despite a high efficacy of preventing severe and fatal COVID-19.

Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

Today, we celebrate the crucial role of infectious disease pharmacists in combating infectious diseases and promoting patient safety.

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.

New findings from clinical trials reveal that Rebyota, a rectally administered treatment, demonstrates improved outcomes in patients with recurrent Clostridioides difficile infection (rCDI).

The presence of certain bacteria in the gastrointestinal tract may limit the effectiveness of antibiotic treatment for Clostridioides difficile.

A study of patients with recurrent Clostridioides difficile infection (rCDI) found that Rebyota, a rectally administered live biotherapeutic, was considered easy, quick, and appealing due to the lack of bowel preparation.

This study found a high proportion of reduced vancomycin susceptibility in C difficile patients, leading to lower rates of sustained clinical response.